PhD Defense by Elda Trevino

Primary tabs

Elda A. Treviño

BME PhD Thesis Defense


Date: May 29th, 2020

Time: 9:00 AM

Bluejeans link: https://bluejeans.com/768678987

Meeting ID: 768 678 987


Advisor: Johnna Temenoff, PhD


Committee Members:

Manu Platt, PhD

Nick Willett, PhD

Edward Botchwey, PhD

Hicham Drissi, PhD (Emory University)


Title: Development of a Controlled-Release Platform for Investigation of Proteases Following Rotator Cuff Tear


Abstract: Surgical reattachment of torn rotator cuff tendons has a high rate of re-tear (failure) and the procedure does not reverse joint tissue degeneration present at the time of surgery. Following rotator cuff tear, all three joint tissues (tendon, muscle, and articular cartilage) develop degenerative changes. A possible cause for the extensive joint tissue degeneration observed following rotator cuff tear is the prolonged activation of proteases, which are specialized enzymes whose primary function is to degrade proteins. Systemic delivery of several protease inhibitors have been tested in human clinical trials to for a variety of diseases including osteoarthritis and osteoporosis, but all have been abandoned due to off-target effects. However, local delivery of protease inhibitors could reduce disease progression without deleterious side effects.

The long-term goal of this dissertation was to understand how proteases contribute to joint tissue degeneration (tendon, muscle, and cartilage) after rotator cuff tear. Understanding the spatial and temporal distribution of upregulated proteases after rotator cuff tear can best inform therapeutic treatments to prevent degeneration, which would result in improved surgical outcomes after rotator cuff tear re-attachment surgery. First, using a rat model of rotator cuff tear that has been shown to replicate degenerative damage seen in humans, we investigated active proteases in each joint tissue over time. Second, we designed a novel microfluidic device to fabricate uniformly sized microparticles that can be loaded with protease inhibitors for subsequent use in vivo. Also, we reinvented a currently available fluorogenic substrate assay for the detection of E-64 (a broad, small molecule cathepsin inhibitor), which was our desired therapeutic. Lastly, we tested our E-64 loaded microparticles system on supraspinatus tendon tissue in our rat model of rotator cuff tear as a test bed to elucidate the effect of sustained release of a broad cathepsin inhibitor on active proteases.



  • Workflow Status: Published
  • Created By: Tatianna Richardson
  • Created: 05/18/2020
  • Modified By: Tatianna Richardson
  • Modified: 05/18/2020


Target Audience

No target audience selected.